Cigna's Q3 Test: Can Healthcare Strength Offset A Giveback In Pharmacy Benefits?

Cigna heads into its third-quarter report with an unusual setup. Management has raised its full-year earnings floor four times in a row, the new chief executive sounded more confident last quarter than the company has in some time, and both operating segments beat internal expectations. Yet the Street is bracing for a year-over-year earnings decline, and sentiment toward the stock has turned noticeably sour. The tension comes down to whether second-quarter strength was durable progress or a timing benefit that the back half of the year is now set to give back.

Analysts expect adjusted earnings of $7.46 a share on revenue of about $73.5 billion. That works out to revenue growth of roughly 5.4% alongside a 4.7% drop in per-share profit from the $7.83 earned a year ago, and a step down from the $7.78 posted last quarter. The whisper number of $7.57 sits modestly above consensus, suggesting some investors expect Cigna to clear the published bar, though not by a wide margin. On the full year, the company is guiding to at least $30.45 a share on roughly $280 billion in revenue. Consensus of $30.51 sits just above that floor, so the Street is not demanding much beyond what management has already committed to. Revenue is a different story: the consensus figure near $289 billion runs well ahead of the company's own outlook, a gap worth monitoring if top-line results land closer to management's framing.

The softer quarterly expectation is largely management's own doing. Executives said the specialty generic and biosimilar benefit that powered the second quarter was pulled forward and will not recur at the same scale, while GLP-1 volumes are moderating as coverage slips and utilization slows. That is why Evernorth's guidance was reaffirmed rather than raised even after a beat. Pharmacy benefit services earnings, which fell to $609 million last quarter on big client renewals and spending tied to the rebate-free Signature model, remain the weak link. A third-quarter PBS result that stabilizes, rather than slides further, would support the view that 2026 is a transition year with a visible bottom. Further deterioration would challenge it.

The offsetting engines need to keep running. Specialty and care services earnings accelerated to 22% growth last quarter, and Cigna Healthcare grew pre-tax earnings 17% with a medical care ratio of 84.5%. With medical cost trend assumed to stay in the high single digits, the healthcare segment's margin discipline, including stop-loss repricing, is the clearest swing factor. Any slippage in the care ratio would matter more than usual because there is little cushion in the full-year guide to absorb it. Investors should also listen for updates on the 2027 PBS selling season, which management described as one of its strongest in years with retention in the mid-90s, since that is the foundation for the recovery story beyond this year.

The market has not paid up for the improving tone. Shares have gained about 4.3% since the last report, essentially matching the S&P 500, and sentiment has swung from mildly bullish before the prior quarter to clearly bearish now. At around $298, the stock trades comfortably above its 200-day average near $281 but roughly 6% below its post-earnings high of $316, leaving it in the middle of its range rather than pressing a breakout.

The central question is whether Cigna can absorb the expected PBS and GLP-1 headwinds while holding its full-year floor intact. A clean quarter that reaffirms or nudges up the $30.45 target, paired with steady medical costs and a flattening pharmacy decline, would keep the momentum narrative alive. A shaky care ratio or a deeper PBS drop would suggest the second-quarter optimism arrived a little early.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.